<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487069</url>
  </required_header>
  <id_info>
    <org_study_id>Alternative Donor HSCT-2015</org_study_id>
    <nct_id>NCT02487069</nct_id>
  </id_info>
  <brief_title>Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell
      transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD)
      and haploidentical related donors(HRD) in the treatment of hematologic malignancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only
      curative therapy for a majority of malignant hematologic diseases, especially acute leukemia.
      HSCT from MSD offers the best results for these diseases, but lack of this donor resource has
      restricted its wide application. HSCT from MUD provides another option, but MUDs still cannot
      satisfy all patients due to unsuccessful donor searches. Almost all patients have an
      available related donor with whom they share a single HLA haplotype (ie, haploidentical
      related donor), and it owns the advantage of immediate availability, especially for those who
      urgently need transplantation.The results of transplantation from HRD have improved
      significantly over the past few years. However, the results from such haploidentical
      transplantation have not formally been compared with those of transplantation in patients
      contemporaneously using MSDs and MUDs for hematologic malignancy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 year</time_frame>
    <description>The primary endpoint is overall survival within 3 years after HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transplantation-related mortality</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft-versus-host disease</measure>
    <time_frame>3 year</time_frame>
    <description>Graft-versus-host disease include acute and chronic Graft-versus-host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>3 year</time_frame>
    <description>Infection includes bacterial, fungal and viral infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematopoietic reconstruction</measure>
    <time_frame>1 year</time_frame>
    <description>Hematopoietic reconstruction includes the time of neutrophil and platelet reconstruction.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>MSD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will received HSCT from MSD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will received HSCT from MUD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will received HSCT from HRD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HSCT from MSD</intervention_name>
    <description>HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.</description>
    <arm_group_label>MSD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HSCT from MUD</intervention_name>
    <description>HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.</description>
    <arm_group_label>MUD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HSCT from HRD</intervention_name>
    <description>HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.</description>
    <arm_group_label>HRD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>CsA is used in all the patients for GVHD prophylaxis.</description>
    <arm_group_label>MSD group</arm_group_label>
    <arm_group_label>MUD group</arm_group_label>
    <arm_group_label>HRD group</arm_group_label>
    <other_name>CsA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>MTX is used in all the patients for GVHD prophylaxis.</description>
    <arm_group_label>MSD group</arm_group_label>
    <arm_group_label>MUD group</arm_group_label>
    <arm_group_label>HRD group</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte globulin</intervention_name>
    <description>ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.</description>
    <arm_group_label>MUD group</arm_group_label>
    <arm_group_label>HRD group</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.</description>
    <arm_group_label>MSD group</arm_group_label>
    <arm_group_label>HRD group</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary disease is acute leukemia/MDS/CML

          -  Receiving allo-HSCT

        Exclusion Criteria:

          -  cardiac dysfunction (particularly congestive heart failure)

          -  hepatic abnormalities (bilirubin â‰¥ 3 mg/dL, aminotransferase&gt; 2 times the upper limit
             of normal)

          -  renal dysfunction (creatinine clearance rate &lt; 30 mL/min)

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiping Fan</last_name>
    <phone>+86-020-62787883</phone>
    <email>hnfzping@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiping Fan</last_name>
      <phone>+86-020-62787883</phone>
      <email>hnfzping@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014 Oct 23;124(17):2735-43. doi: 10.1182/blood-2014-04-571570. Epub 2014 Sep 11.</citation>
    <PMID>25214441</PMID>
  </reference>
  <reference>
    <citation>Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006 Apr 15;107(8):3065-73. Epub 2005 Dec 27.</citation>
    <PMID>16380454</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2015</study_first_submitted>
  <study_first_submitted_qc>June 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

